The treatment of DLBCL-derived cell lines with inhibitors of the multi-subunit IκB kinase (IKK) complex, the main activator of the NF-κB pathway, demonstrated that these drugs block the proliferation of ABC-DLBCL cells before inducing cell death [65]. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.